Nom du produit:diisopropyl (E)-diazene-1,2-dicarboxylate
IUPAC Name:(E)-N-{[(propan-2-yloxy)carbonyl]imino}(propan-2-yloxy)formamide
- CAS：2446-83-5
- Formule moléculaire：C8H14N2O4
- Pureté：98%
- Numéro de catalogue：CM303397
- Poids moléculaire：202.21
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2446-83-5
- Formule moléculaire:C8H14N2O4
- Point de fusion:-
- Code SMILES:O=C(/N=N/C(OC(C)C)=O)OC(C)C
- Densité:
- Numéro de catalogue:CM303397
- Poids moléculaire:202.21
- Point d'ébullition:
- N° Mdl:
- Stockage:Store at room temperature
Category Infos
- Aliphatic Chain Compounds
- Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.
Column Infos
- MK-1084
- Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.
Recherche 
+86 21 5895 0110 
